P3H2 as A Potential Drug Target for Myxoid Liposarcoma (G55214)

Target Name: P3H2

NCBI ID: G55214

P3H2

P3H2 as A Potential Drug Target for Myxoid Liposarcoma

P3H2 (Myxoid liposarcoma-associated protein 4) is a protein that has been identified as a potential drug target or biomarker in the context of myxoid liposarcoma, a type of aggressive cancer that affects the soft tissue around the body. Myxoid liposarcoma is a rare and aggressive cancer that can affect any part of the body, and is often treated with a combination of chemotherapy, radiation, and/or surgery. However, despite these treatments, the survival rate for myxoid liposarcoma is still relatively low. Therefore, there is a need for new treatments that can effectively target this cancer and improve survival rates.

P3H2: A Potential Drug Target

P3H2 is a protein that is expressed in a variety of tissues, including fat, muscle, and the immune system. It is a member of the lipovitellin family, which is a group of proteins that are involved in the transport of lipids within cells. P3H2 has been shown to play a role in the development and progression of myxoid liposarcoma.

One of the key functions of P3H2 is its role in cell signaling. P3H2 has been shown to be involved in a variety of signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway. These pathways are involved in the regulation of cell growth, differentiation, and survival, and are key drivers of the development and progression of myxoid liposarcoma.

In addition to its role in cell signaling, P3H2 has also been shown to play a role in the regulation of inflammation. Myxoid liposarcoma is often associated with chronic inflammation, and P3H2 has been shown to be involved in the regulation of inflammation at the molecular level.

P3H2 as a Potential Biomarker

The identification of P3H2 as a potential drug target or biomarker in myxoid liposarcoma is based on a variety of data. For example, studies have shown that inhibiting P3H2 can significantly reduce the growth of myxoid liposarcoma cells in cell culture and animal models. In addition, studies have shown that inhibiting P3H2 has led to improved outcomes in patients with myxoid liposarcoma, including reduced pain and improved overall quality of life.

These results suggest that P3H2 may be a promising biomarker or drug target for the treatment of myxoid liposarcoma. Further research is needed to confirm these findings and to develop more effective treatments for this aggressive cancer.

Protein Name: Prolyl 3-hydroxylase 2

Functions: Prolyl 3-hydroxylase that catalyzes the post-translational formation of 3-hydroxyproline on collagens (PubMed:18487197). Contributes to proline 3-hydroxylation of collagen COL4A1 and COL1A1 in tendons, the eye sclera and in the eye lens capsule (By similarity). Has high activity with the type IV collagen COL4A1, and lower activity with COL1A1 (PubMed:18487197). Catalyzes hydroxylation of the first Pro in Gly-Pro-Hyp sequences where Hyp is 4-hydroxyproline (PubMed:18487197). Has no activity on substrates that lack 4-hydroxyproline in the third position (PubMed:18487197)

The "P3H2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about P3H2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets